Vinge advised the lead investor ARCH Venture Partners on the deal. Moleculent AB, a company pioneering technology to study the communication between cells in human tissue,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented ARCH Venture Partners on the deal. ARCH Venture Partners led the $270 million Series A financing of Orbital Therapeutics, a company focused on enhancing...
You must be a Standard 1 Year member to access this content.
Proskauer advised ARCH Venture Partners on the transaction. ARCH Venture Partners (“ARCH”) announced the closing of ARCH Venture Fund XII. The fund closed with $2.975 billion...
You must be a Standard 1 Year member to access this content.
